I

Inno-Gene SA
WSE:IGN

Watchlist Manager
Inno-Gene SA
WSE:IGN
Watchlist
Price: 5.04 PLN -0.4% Market Closed
Market Cap: 17.7m PLN
Have any thoughts about
Inno-Gene SA?
Write Note

Inno-Gene SA
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inno-Gene SA
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
I
Inno-Gene SA
WSE:IGN
Gross Profit
-zł204k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Medicofarma Biotech SA
WSE:MDB
Gross Profit
zł491.4k
CAGR 3-Years
-14%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
R
Ryvu Therapeutics SA
WSE:RVU
Gross Profit
zł40.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
13%
S
Selvita SA
WSE:SLV
Gross Profit
zł258.9m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inno-Gene SA
Glance View

Market Cap
17.7m PLN
Industry
Life Sciences Tools & Services

Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.

IGN Intrinsic Value
2.03 PLN
Overvaluation 60%
Intrinsic Value
Price
I

See Also

What is Inno-Gene SA's Gross Profit?
Gross Profit
-204k PLN

Based on the financial report for Jun 30, 2024, Inno-Gene SA's Gross Profit amounts to -204k PLN.

Back to Top